CMTNS and ONLS , with a significant improvement of respectively of 8 % ( 0.4 % - 16.2 % ) and 12.1 % ( 2 % - 23.2 % ) in the HD group versus the pool of all other groups , appear to be the most sensitive clinical endpoints to treatment despite their quasi-stability over one year under Placebo .